GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision
Menée à l'aide d'un modèle murin de rétinoblastome, cette étude démontre que l'injection intratumorale d'un hydrogel contenant des lymphocytes CAR-T spécifiques du ganglioside GD2 freine le développement tumoral tout en préservant la vision
Retinoblastoma (RB) is a pediatric retinal tumor that overexpresses the ganglioside GD2. Although it is treatable in patients with early diagnosis, patients may lose one or two eyes. We generated GD2-specific chimeric antigen receptor T lymphocytes (GD2.CAR-Ts) and locally delivered them to mice with an in situ grafting RB. We showed that, when used in combination with the local release of interleukin-15 and an injectable hydrogel, GD2.CAR-Ts successfully eliminate RB tumor cells without impairing mouse vision.
Nature Cancer 2020